Table 1.

Patient characteristics; N number of patients and by tumour type (HCC hepatocellular cancers, ORL head and neck cancers, Colon ca colorectal cancers); mSv equivalent dose PET component; mean radiopharmaceutical activity applied (MBq); ±SD standard deviation; age (years); mean delay (time window between start of the first examination and the start of the second examination)

Radiotracer	N, tumour type	mSV	Mean activity (MBq)	Mean activity SD	Age (a)	Mean Delay (hh:mm:ss)
18F-FDG	N = 20 (lung = 6, lymphoma 3, ORL 3, breast 2, thyroid 2, melanoma 2, HCC 1, Colon Ca 1	5.0	265.6	65.8	67.9	00:47:08
18F-PSMA-1007	N = 16 (14 biochemical recurrence, 2 primary)	5.4	243.9	14.0	75.5	00:57:21
68Ga-DOTA-TOC	N = 8 (SSTR expressing neuroendcrine tumours)	3.5	154.1	12.0	65.3	01:15:21